Genotype-based therapeutic approach for colorectal cancer: State of the art and future perspectives

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1095-1108

  Fogli, Stefano ^a   Caraglia, Michele ^b  

^a UNIVERSITY OF PISA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anticancer drugs; Colorectal cancer; Personalized therapy; Pharmacogenetics; Polymorphism

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GLUCOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; MERCAPTOPURINE; OXALIPLATIN; PANITUMUMAB; TAMOXIFEN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHATE GLUCOSYLTRANSFERASE 1A1;

ALLELE; ALOPECIA; ARTERY EMBOLISM; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HEREDITY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTESTINE PERFORATION; LETHARGY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENETICS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RASH; RELIABILITY; REVIEW; STOMACH CANCER; STOMATITIS; VARIABLE NUMBER OF TANDEM REPEAT; COLORECTAL TUMOR;

COLORECTAL NEOPLASMS; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 67649497365     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902889775     Document Type: Review

References (128)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592
2. Cancer Facts and Figures. American Cancer Society, 2008. Available from: www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf. [Last accessed 29 Mar 2009]
3. Danesi R, De Braud F, Fogli S, et al. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 2001;22:420-426 •• This article focuses on the application of pharmacogenetics in the characterization of differences in the pharmacokinetics and pharmacodynamics of anticancer agents among individuals. (Pubitemid 32718634)
4. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549 (Pubitemid 36159890)
5. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 2008;448:63-76
6. Liu W, Innocenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012 (Pubitemid 36323704)
7. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-2138
8. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491
9. Frazer KA, Ballinger DG, et al. International HapMap Consortium. Nature 2007;449:851-861
10. Sobrero A, Guglielmi A, Grossi F, et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000;27(Suppl 10):72-77 (Pubitemid 30781969)
11. Zhang ZG, Harstrick A, Rustum YM. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin Oncol 1992;19(Suppl 3):10-15
12. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815 (Pubitemid 27074252)
13. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-1426 (Pubitemid 19245111)
14. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418 (Pubitemid 19245110)
15. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-3775
16. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-1887 (Pubitemid 23304611)
17. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906 (Pubitemid 24109275)
18. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-250 (Pubitemid 27020580)
19. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-3559 (Pubitemid 29517927)
20. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806
21. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23:8671-8678 (Pubitemid 46211510)
22. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23:1819-1825 (Pubitemid 46211360)
23. Kosmider S, Lipton L. Adjuvant therapies for colorectal cancer. World J Gastroenterol 2007;13:3799-3805 (Pubitemid 47277226)
24. Pentheroudakis G, Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 2002;22:3589-3596 (Pubitemid 36132834)
25. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106 (Pubitemid 33049527)
26. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292 (Pubitemid 32366981)
27. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704 (Pubitemid 41007824)
28. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998;42(Suppl):S31-43 (Pubitemid 128690127)
29. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412 (Pubitemid 28510873)
30. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418 (Pubitemid 28510874)
31. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914 (Pubitemid 30727802)
32. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071 (Pubitemid 28518143)
33. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-1865 (Pubitemid 26419675)
34. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235
35. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-2744
36. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-108 (Pubitemid 28125772)
37. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947 (Pubitemid 30644117)
38. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237 (Pubitemid 41095086)
39. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30 (Pubitemid 41095110)
40. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351 (Pubitemid 38702845)
41. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 2005;23:3501
42. Mano MS, Duhoux F. Colon cancer: update on adjuvant therapy. Clin Colorectal Cancer 2008;7:178-183 (Pubitemid 351758147)
43. Wolmark N, Wieand HS, Keubler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07 [abstract 3500]. J Clin Oncol 2005;23:16s
44. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-109 (Pubitemid 350003057)
45. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2-8 (Pubitemid 34977157)
46. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285-289
47. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-115 (Pubitemid 30114656)
48. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-2460 (Pubitemid 23100476)
49. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005;103:2435-2446 (Pubitemid 40800520)
50. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-9274 (Pubitemid 46260183)
51. Blanke CD. Gefitinib in colorectal cancer: if wishes were horses. J Clin Oncol 2005;23:5446-5449 (Pubitemid 46300133)
52. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208 (Pubitemid 41079832)
53. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345 (Pubitemid 38944402)
54. Van Cutsem E, Nowacki M, Lang S. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract 4000]. J Clin Oncol 2007;25:18s
55. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proc Am Soc Clin Oncol 2007;25:4035
56. Maughan T. Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial [abstract 4070]. J Clin Oncol 2007;25:18s
57. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract 3520]. J Clin Oncol 2005;23:251s
58. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial of panitumamab plus best supportive care versus best supportive care alone in patients with metastatic colorectal cancer [abstract CP-1]. Paper presented at the American Association for Cancer Research (AACR) Meeting April 1-5, 2006, Washington, DC, USA
59. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
60. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676 (Pubitemid 36749215)
61. AVASTIN™ (Bevacizumab). FDA labelling information. FDA/Center for Drug Evaluation and Research, 2004. Available from: www.fda.gov/cder/foi/ label/2004/125085lbl.pdf. [Last accessed 29 Mar 2009]
62. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 (Pubitemid 38702844)
63. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract 2]. Proc Am Soc Clin Oncol 2005;23:1s
64. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508 (Pubitemid 46243494)
65. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982 (Pubitemid 43313687)
66. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
67. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70 (Pubitemid 33757985)
68. Garcia V, García JM, Peña C, et al. Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res 2006;12:2095-2100
69. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-1786 (Pubitemid 32230880)
70. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412
71. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229 (Pubitemid 27419335)
72. Hitre E, Budai B, Adleff V, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723-730 (Pubitemid 41345324)
73. Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365-1369 (Pubitemid 46260023)
74. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124 (Pubitemid 37204028)
75. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003;63:6004-6007 • Discusses the relevance of the double polymorphism in the TS tandem repeat sequence, the SNP and the VNTR, in predicting the clinical outcome of 5-fluorouracil-based chemotherapy. (Pubitemid 37187503)
76. Marcuello E, Altés A, del Rio E, et al. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;112:733-737 (Pubitemid 39435256)
77. Kawakami K, Graziano F, Watanabe G, et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005;11:3778-3783 (Pubitemid 40685596)
78. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006;24:1883-1891 (Pubitemid 46638987)
79. Graziano F, Ruzzo A, Loupakis F, et al. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Br J Cancer 2008;99:716-721
80. Kawakami K. Thymidylate synthase gene in pharmacogenetics. Curr Pharmacogenomics 2004;2:137-147 (Pubitemid 38842547)
81. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenet 2004;14:319-327 (Pubitemid 38638919)
82. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008;8:278-288 (Pubitemid 352038307)
83. Martinez-Balibrea E, Abad A, Aranda E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 2008;44:1229-1237
84. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-3541
85. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006;45:567-592
86. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950 (Pubitemid 38496249)
87. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006;5:2895-2904 • Evaluation of frequencies and effects of several DPYD SNPs on 5-FU tolerance. (Pubitemid 44849017)
88. Morel A, Boisdron-Celle M, Fey L, et al. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007;40:11-17 (Pubitemid 46014150)
89. Sohn KJ, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004;96:134-144 (Pubitemid 38195904)
90. Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365-1369 (Pubitemid 46260023)
91. Arnould S, Hennebelle I, Canal P, et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003;39:112-119 (Pubitemid 36005433)
92. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-6217 (Pubitemid 41262950)
93. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-166
94. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-354 (Pubitemid 39037082)
95. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-1254 (Pubitemid 46640571)
96. Le Morvan V, Smith D, Laurand A, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 2007;8:1693-1703
97. Monzo M, Moreno I, Navarro A, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007;72:364-370 (Pubitemid 351238151)
98. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25:1639-1648
99. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;94:936-942 (Pubitemid 34778092)
100. Kweekel DM, Koopman M, Antonini NF, et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008;99:1316-1321 • Discusses the impact of the GSTP1 codon 105 polymorphism on the response to irinotecan-based chemotherapy in patients with metastatic CRC.
101. Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006;94:281-286 (Pubitemid 43151548)
102. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005;11:2175-2179 (Pubitemid 40490175)
103. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predicts the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388 (Pubitemid 41103619)
104. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1'28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061-3068 (Pubitemid 46638941)
105. Lankisch TO, Schulz C, Zwingers T, et al. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008;17:695-701
106. Hoskins JM, Marcuello E, Altes A, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008;14:1788-1796
107. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427-1434
108. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-3718 (Pubitemid 47372612)
109. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and k-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237 (Pubitemid 47325606)
110. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765
111. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
112. Spindler KL, Nielsen JN, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006;66:500-504 (Pubitemid 44332722)
113. Kweekel DM, Gelderblom H, Van der Straaten T, et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008;99:275-282
114. Marsh S, Mallon MA, Goodfellow P, et al. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005;6:873-877 (Pubitemid 41724361)
115. Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004;10:433-439 (Pubitemid 38173979)
116. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412
117. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690-2698
118. Ezzeldin HH, Lee AM, Mattison LK, et al. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005;11:8699-8705 (Pubitemid 43005919)
119. Zhang X, Soong R, Wang K, et al. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol 2007;85:337-346 (Pubitemid 47025913)
120. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536 (Pubitemid 41079782)
121. Yong WP, Innocenti F. Translation of pharmacogenetic knowledge into cancer therapeutics. Clin Adv Hematol Oncol 2007;5:698-706 (Pubitemid 351699413)
122. Bromley CM, Close S, Cohen N, et al. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J 2009;9:14-22
123. Twyman RM. SNP discovery and typing technologies for pharmacogenomics. Curr Top Med Chem 2004;4:1423-1431 (Pubitemid 39242883)
124. Koch WH. Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov 2004;3:749-761 (Pubitemid 39242827)
125. Keen-Kim D, Grody WW, Richards CS. Microelectronic array system for molecular diagnostic genotyping: NanogenNanoChip 400 and molecular biology workstation. Expert Rev Mol Diagn 2006;6:287-294 (Pubitemid 44174335)
126. Xu H, Gregory SG, Hauser ER, et al. SNPselector: a web tool for selecting SNPs for genetic association studies. Bioinformatics 2005;21:4181-4186 (Pubitemid 41672110)
127. Grover D, Woodfield AS, Verma R, et al. QuickSNP: an automated web server for selection of tagSNPs. Nucleic Acids Res 2007;35(Web Server issue):W115-20
128. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007;81:328-345 •• A knowledge base containing information on the relationships between drugs, diseases/phenotypes and genes involved in pharmacokinetics and pharmacodynamics. Available from: http://www.pharmgkb.org/. [Last accessed 29 Mar 2009] (Pubitemid 46364488)